Literature DB >> 8875302

Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention.

W R Jarvis1.   

Abstract

Approximately 2 million nosocomial infections occur annually in the United States. These infections result in substantial morbidity, mortality, and cost. The excess duration of hospitalization secondary to nosocomial infections has been estimated to be 1 to 4 days for urinary tract infections, 7 to 8.2 days for surgical site infections, 7 to 21 days for bloodstream infections, and 6.8 to 30 days for pneumonia. The estimated mortalities associated with nosocomial bloodstream infections and pneumonia are 23.8% to 50% and 14.8% to 71% (overall), or 16.3% to 35% and 6.8% to 30% (attributable), respectively. The estimated average costs of these infections are $558 to $593 for each urinary tract infection, $2,734 for each surgical site infection, $3,061 to $40,000 for each bloodstream infection, and $4,947 for each pneumonia. Even minimally effective infection control programs are cost-effective. In countries with prospective payment systems based on diagnosis-related groups, hospitals lose from $583 to $4,886 for each nosocomial infection. As administrators focus on cost containment, increased support should be given to infection control programs so that preventable nosocomial infections and their associated expenditures can be averted.

Entities:  

Mesh:

Year:  1996        PMID: 8875302     DOI: 10.1086/647371

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  73 in total

1.  Route and type of nutrition influence mucosal immunity to bacterial pneumonia.

Authors:  B K King; K A Kudsk; J Li; Y Wu; K B Renegar
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

2.  Development of a clinical data warehouse for hospital infection control.

Authors:  Mary F Wisniewski; Piotr Kieszkowski; Brandon M Zagorski; William E Trick; Michael Sommers; Robert A Weinstein
Journal:  J Am Med Inform Assoc       Date:  2003-06-04       Impact factor: 4.497

3.  Safety and efficacy of a novel silver-impregnated urinary catheter system for preventing catheter-associated bacteriuria: a pilot randomized clinical trial.

Authors:  Anne-Marie Leuck; James R Johnson; Matthew A Hunt; Kush Dhody; Kazem Kazempour; Patricia Ferrieri; Susan Kline
Journal:  Am J Infect Control       Date:  2015-03-01       Impact factor: 2.918

4.  Effect of guideline implementation on costs of hand hygiene.

Authors:  Patricia W Stone; Sumya Hasan; Dave Quiros; Elaine L Larson
Journal:  Nurs Econ       Date:  2007 Sep-Oct       Impact factor: 1.085

5.  What do central venous catheter-associated bloodstream infections have to do with bundles?g.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-07       Impact factor: 2.471

6.  Physician 'defiance' towards hand hygiene compliance: Is there a theory-practice-ethics gap?

Authors:  Manfred Mortell; Hanan H Balkhy; Elias B Tannous; Mei Thiee Jong
Journal:  J Saudi Heart Assoc       Date:  2013-05-09

Review 7.  Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs.

Authors:  Günter Kampf; Axel Kramer
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  Statewide costs of health care-associated infections: estimates for acute care hospitals in North Carolina.

Authors:  Deverick J Anderson; Deborah G Pyatt; David J Weber; William A Rutala
Journal:  Am J Infect Control       Date:  2013-02-27       Impact factor: 2.918

Review 9.  Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis.

Authors:  S M Jacobsen; D J Stickler; H L T Mobley; M E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

10.  The economic impact of Staphylococcus aureus infection in New York City hospitals.

Authors:  R J Rubin; C A Harrington; A Poon; K Dietrich; J A Greene; A Moiduddin
Journal:  Emerg Infect Dis       Date:  1999 Jan-Feb       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.